Literature DB >> 10606451

Long-term drusen study.

D Sarraf1, T Gin, F Yu, A Brannon, S L Owens, A C Bird.   

Abstract

PURPOSE: To determine the yearly incidence of visual loss in the fellow eyes of patients with unilateral neovascular age-related macular degeneration (ARMD) and to assess the drusen characteristics portending the greatest risk for this outcome.
METHODS: A total of 101 patients with unilateral exudative ARMD and drusen only in the fellow eye were entered into the study and prospectively followed up to 9 years. Visual acuity, color fundus photography, fluorescein angiography, and grading of drusen characteristics were obtained for each patient on entry into the study. Patients were followed at annual intervals with color fundus photography. The study endpoint was the development of choroidal neovascularization (CNV) or geographic atrophy (GA) in the fellow eye.
RESULTS: Yearly incidence rates for the development of an endpoint lesion were between 5 and 14%. The risk of CNV peaked at 4 years and dissipated thereafter. Longer follow-up was associated with a slightly increased incidence of GA. Greater drusen number was most highly associated with the development of an endpoint lesion. Drusen size and confluence were also significant.
CONCLUSIONS: The risk of CNV in patients with ARMD is heralded by an increase in the number, size, and confluence of drusen. This risk eventually declines and is followed by later increased risk of GA.

Entities:  

Mesh:

Year:  1999        PMID: 10606451     DOI: 10.1097/00006982-199911000-00006

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

Review 1.  Basement membranes and artificial substrates in cell transplantation.

Authors:  Carl Sheridan; Rachel Williams; Ian Grierson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-20       Impact factor: 3.117

Review 2.  Age-related macular degeneration--emerging pathogenetic and therapeutic concepts.

Authors:  Karen M Gehrs; Don H Anderson; Lincoln V Johnson; Gregory S Hageman
Journal:  Ann Med       Date:  2006       Impact factor: 4.709

3.  Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis.

Authors:  Jose S Pulido
Journal:  Trans Am Ophthalmol Soc       Date:  2002

4.  Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration.

Authors:  Graham F Merry; Marion R Munk; Robert S Dotson; Michael G Walker; Robert G Devenyi
Journal:  Acta Ophthalmol       Date:  2016-12-18       Impact factor: 3.761

Review 5.  Negative Regulators of Angiogenesis, Ocular Vascular Homeostasis, and Pathogenesis and Treatment of Exudative AMD.

Authors:  Mitra Farnoodian; Christine M Sorenson; Nader Sheibani
Journal:  J Ophthalmic Vis Res       Date:  2018 Oct-Dec

Review 6.  Laser treatment of drusen to prevent progression to advanced age-related macular degeneration.

Authors:  Gianni Virgili; Manuele Michelessi; Maurizio B Parodi; Daniela Bacherini; Jennifer R Evans
Journal:  Cochrane Database Syst Rev       Date:  2015-10-23

Review 7.  Age-related macular degeneration and changes in the extracellular matrix.

Authors:  Małgorzata Nita; Barbara Strzałka-Mrozik; Andrzej Grzybowski; Urszula Mazurek; Wanda Romaniuk
Journal:  Med Sci Monit       Date:  2014-06-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.